Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Healthcare (Basel) ; 10(10)2022 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-36292388

RESUMEN

Premature mortality is defined as death that occurs before the average age of death for a particular population. Although premature mortality is a public health problem globally, the literature indicates no bibliometric studies that have made a holistic evaluation of the publications on this issue. This study aims to explore the characteristics of the publications on premature mortality in terms of the number of publications, citations, countries, collaboration, and the author's productivity and to further identify the trending keyword and relevant research topics. All the articles related to premature mortality data were retrieved from the Web of Science (WOS) database using the search terms "premature death," "premature mortality," or "years of life loss." The retrieved articles were downloaded in a BibTeX format file. A Bibliometrix package from R software was used to perform bibliometric analyses. A total of 1060 original research articles and reviews have been published since 1971, with a total of 5499 contributing authors. The number of publications has increased substantially in the past decade. The annual percentage growth rate of publications is 5.08%. The United States is the leading country in this area of research with the highest number of publications (n = 280), the highest total citation (17,378), and the most activity in collaboration. Our thematic map suggests that the cluster for cardiovascular disease became the main research domain in this field, while the cluster for air pollution is an important topic for future research. Additionally, neurodegeneration is another cluster of research that should be developed further and connected with premature mortality. These bibliometric findings hopefully will help scholars better understand the global overview of premature mortality and provide information for potential collaborators, with the information promising attractive areas for future research.

2.
CNS Neurol Disord Drug Targets ; 20(8): 736-754, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34348635

RESUMEN

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by sleep, behavioral, memory, and cognitive deteriorations. Sleep disturbance (SD) is a major disease burden in AD, which has a reciprocal relationship with AD pathophysiology. It aggravates memory, behavioral, and cognitive complications in AD. Different studies have found that melatonin hormone levels reduce even in the pre-clinical stages of AD. Melatonin is the primary sleep-regulating hormone and a potent antioxidant with neuroprotective roles. The decrease in melatonin levels can thus promote SD and AD neuropathology. Exogenous melatonin has the potential to alleviate neuropathology and SD in AD by different mechanisms. Various studies have been conducted to assess the efficacy of exogenous melatonin to treat SD in AD. Though most of the studies suggest that melatonin is useful to ameliorate SD in AD, the remaining studies show opposite results. The timing, dosage, and duration of melatonin administration along with disease condition, genetic, environmental, and some other factors can be responsible for the discrepancies between the studies. More extensive trials with longer durations and higher dosage forms and studies including bright light therapy and melatonin agonists (ramelteon, agomelatine, and tasimelteon) should be performed to determine the efficacy of melatonin to treat SD in AD.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Antioxidantes/uso terapéutico , Melatonina/uso terapéutico , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Ritmo Circadiano/fisiología , Humanos , Sueño/fisiología , Factores de Tiempo
3.
Pharmaceuticals (Basel) ; 14(3)2021 Feb 25.
Artículo en Inglés | MEDLINE | ID: mdl-33669084

RESUMEN

Drug-related problems (DRPs) in the elderly include polypharmacy, potentially inappropriate medications, nonadherence, and drug-related falls. In this systematic review and meta-analysis, the prevalence of DRPs and complementary and alternative medicine (CAM) use among the Malaysian elderly was estimated. PubMed, Scopus, Web of Science, and Google Scholar databases were searched to identify studies published since their inception up to 24 August 2020. A random-effects model was used to generate the pooled prevalence of DRPs along with its corresponding 95% confidence interval (CI). The heterogeneity of the results was estimated using the I2 statistics, and Cochran's Q test and sensitivity analyses were performed to confirm the robustness of the results. We identified 526 studies, 23 of which were included in the meta-analysis. (n = 29,342). The pooled prevalence of DRPs among Malaysian elderly was as follows: (1) polypharmacy: 49.5% [95% CI: 20.5-78.6], (2) potentially inappropriate medications: 28.9% [95% CI: 25.4-32.3], (3) nonadherence to medications: 60.6% [95% CI: 50.2-70.9], and (4) medication-related falls 39.3% [95% CI: 0.0-80.8]. Approximately one in two Malaysian elderly used CAM. The prevalence of polypharmacy and potentially inappropriate medications among the Malaysian elderly population was high, calling for measures and evidence-based guidelines to ensure the safe medication use.

4.
Front Immunol ; 11: 1477, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32793202

RESUMEN

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ involvement, including the skin, joints, kidneys, lungs, central nervous system and the haematopoietic system, with a large number of complications. Despite years of study, the etiology of SLE remains unclear; thus, safe and specifically targeted therapies are lacking. In the last 20 years, researchers have explored the potential of nutritional factors on SLE and have suggested complementary treatment options through diet. This study systematically reviews and evaluates the clinical and preclinical scientific evidence of diet and dietary supplementation that either alleviate or exacerbate the symptoms of SLE. For this review, a systematic literature search was conducted using PubMed, Scopus and Google Scholar databases only for articles written in the English language. Based on the currently published literature, it was observed that a low-calorie and low-protein diet with high contents of fiber, polyunsaturated fatty acids, vitamins, minerals and polyphenols contain sufficient potential macronutrients and micronutrients to regulate the activity of the overall disease by modulating the inflammation and immune functions of SLE.


Asunto(s)
Dietoterapia , Suplementos Dietéticos , Lupus Eritematoso Sistémico/inmunología , Animales , Dieta , Ácidos Grasos Insaturados/uso terapéutico , Humanos , Inmunomodulación , Lupus Eritematoso Sistémico/dietoterapia , Minerales/uso terapéutico , Polifenoles/uso terapéutico
5.
Autoimmun Rev ; 18(11): 102392, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31520805

RESUMEN

BACKGROUND: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease where chronic inflammation and tissue or organ damage is observed. Due to various suspected causes, inadequate levels of vitamin D (a steroid hormone with immunomodulatory effects) has been reported in patients with SLE, however, contradictory. AIMS: The aim of this systematic review and meta-analysis was to evaluate the serum levels of vitamin D in patients with SLE in compared to healthy controls. METHODS: PubMed, SCOPUS, ScienceDirect and Google Scholar electronic databases were searched systematically without restricting the languages and year (up to March 2, 2019) and studies were selected based on the inclusion criteria. Mean difference (MD) along with 95% confidence intervals (CI) were used and the analyses were carried out by using a random-effects model. Different subgroup and sensitivity analyses were conducted. Study quality was assessed by the modified Newcastle-Ottawa Scale (NOS) and publication bias was evaluated by a contour-enhanced funnel plot, Begg's and Egger's tests. RESULTS: We included 34 case-control studies (2265 SLE patients and 1846 healthy controls) based on the inclusion criteria. Serum levels of vitamin D was detected significantly lower in the SLE patients than that in the healthy controls (MD: -10.44, 95% CI: -13.85 to -7.03; p < .00001). SLE patients from Asia (MD: -13.75, 95% CI: -21.45 to -6.05; p = .0005), South America (MD: -3.16, 95% CI: -4.62 to -1.70; p < .0001) and Africa (MD: -16.15, 95% CI: -23.73 to -8.56; p < .0001); patients residing below 37° latitude (MD: -11.75, 95% CI: -15.79 to -7.70; p < .00001); serum vitamin D during summer season (MD: -7.89, 95% CI: -11.70 to -4.09; p < .0001), patients without vitamin D supplementation (MD: -15.57, 95% CI: -19.99 to -11.14; p < .00001) or on medications like hydroxychloroquine, corticosteroids or immunosuppressants without vitamin D supplementation (MD: -16.46, 95% CI: -23.86 to -9.05; p < .0001) are in higher risk in presenting inadequate serum levels of vitamin D. The results remained statistically significant from different sensitivity analyses which represented the robustness of this meta-analysis. According to the NOS, 91.2% of the studies were considered as of high methodological quality (low risk of bias). No significant publication bias was detected from contour-enhanced and trim and fill funnel plots or Begg's test. CONCLUSION: Inadequate levels of serum vitamin D is significantly high in patients with SLE compared to healthy subjects, therefore, vitamin D supplementation with regular monitoring should be considered as part of their health management plans.


Asunto(s)
Lupus Eritematoso Sistémico/sangre , Vitamina D/sangre , Vitaminas/sangre , Estudios de Casos y Controles , Humanos
6.
Curr Med Chem ; 25(39): 5395-5431, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-27528060

RESUMEN

Over the years, natural products have shown success as antidiabetics in in vitro, in vivo studies and clinical trials. Because natural product-derived drugs are more affordable and effective with fewer side-effects compared to conventional therapies, pharmaceutical research is increasingly leaning towards the discovery of new antidiabetic drugs from natural products targeting pathways or components associated with type 2 diabetes mellitus (T2DM) pathophysiology. However, the drug discovery process is very lengthy and costly with significant challenges. Therefore, various techniques are currently being developed for the preclinical research phase of drug discovery with the aim of drug development with less time and efforts from natural products. In this review, we have provided an update on natural products including fruits, vegetables, spices, nuts, beverages and mushrooms with potential antidiabetic activities from in vivo, in vitro and clinical studies. Synergistic interactions between natural products and antidiabetic drugs, and potential antidiabetic active compounds from natural products are also documented to pave the way for combination treatment and new drug discovery, respectively. Additionally, a brief idea of the drug discovery process along with the challenges that arise during drug development from natural products and the methods to conquer those challenges are discussed to create a more convenient future drug discovery process.


Asunto(s)
Productos Biológicos/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Productos Biológicos/química , Productos Biológicos/farmacología , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/patología , Descubrimiento de Drogas , Gliclazida/química , Gliclazida/farmacología , Gliclazida/uso terapéutico , Transportador de Glucosa de Tipo 4/metabolismo , Humanos , Hipoglucemiantes/química , Hipoglucemiantes/farmacología , Metformina/química , Metformina/farmacología , Metformina/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Compuestos de Sulfonilurea/química , Compuestos de Sulfonilurea/farmacología , Compuestos de Sulfonilurea/uso terapéutico
7.
Curr Drug Metab ; 18(1): 50-61, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-27396919

RESUMEN

Parkinson's disease (PD) is characterized by neurodegeneration and a progressive functional impairment of the midbrain nigral dopaminergic neurons. The cause remains unknown; however, several pathological processes and central factors, such as protein aggregation, mitochondrial dysfunction, iron accumulation, neuroinflammation and oxidative stress, have been reported. The current treatment method primarily targets symptoms by using anti-Parkinson drugs such as levodopa, carbidopa, dopamine (DA) agonists, monoamine oxidase type B inhibitors and anticholinergics to replace DA. When drug therapy is not satisfactory, surgical treatments are recommended. Unfortunately, the existing conventional strategies that target PD are associated with numerous side effects and possess an economic burden. Therefore, novel therapeutic approaches that regulate the pathways leading to neuronal death and dysfunction are necessary. For many years, nature has provided the primary resource for the discovery of potential therapeutic agents. Remarkably, many natural products from medicinal plants, fruits and vegetables have been demonstrated to be efficacious anti-Parkinson agents. These products possess neuroprotective properties as a result of not only their wellrecognized anti-oxidative and anti-inflammatory activities but also their inhibitory roles regarding iron accumulation, protein misfolding and the maintenance of proteasomal degradation, as well as mitochondrial homeostasis. The aim of this review is to report the available anti-Parkinson agents based on natural products and delineate their therapeutic actions, which act on various pathways. Overall, this review emphasizes the types of natural products that are potential future resources in the treatment of PD as novel regimens or supplementary agents.


Asunto(s)
Productos Biológicos/uso terapéutico , Descubrimiento de Drogas , Enfermedad de Parkinson/tratamiento farmacológico , Humanos
8.
Oxid Med Cell Longev ; 2016: 5137431, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27721914

RESUMEN

Cumulatively, degenerative disease is one of the most fatal groups of diseases, and it contributes to the mortality and poor quality of life in the world while increasing the economic burden of the sufferers. Oxidative stress and inflammation are the major pathogenic causes of degenerative diseases such as rheumatoid arthritis (RA), diabetes mellitus (DM), and cardiovascular disease (CVD). Although a number of synthetic medications are used to treat these diseases, none of the current regimens are completely safe. Phytochemicals (polyphenols, carotenoids, anthocyanins, alkaloids, glycosides, saponins, and terpenes) from natural products such as dietary fruits, vegetables, and spices are potential sources of alternative medications to attenuate the oxidative stress and inflammation associated with degenerative diseases. Based on in vitro, in vivo, and clinical trials, some of these active compounds have shown good promise for development into novel agents for treating RA, DM, and CVD by targeting oxidative stress and inflammation. In this review, phytochemicals from natural products with the potential of ameliorating degenerative disease involving the bone, metabolism, and the heart are described.


Asunto(s)
Antiinflamatorios/administración & dosificación , Antioxidantes/administración & dosificación , Artritis Reumatoide/terapia , Enfermedades Cardiovasculares/terapia , Diabetes Mellitus/terapia , Dieta Saludable , Suplementos Dietéticos , Inflamación/terapia , Estrés Oxidativo/efectos de los fármacos , Fitoquímicos/administración & dosificación , Animales , Antiinflamatorios/aislamiento & purificación , Antioxidantes/aislamiento & purificación , Antirreumáticos/administración & dosificación , Artritis Reumatoide/metabolismo , Enfermedades Cardiovasculares/metabolismo , Enfermedades Cardiovasculares/mortalidad , Diabetes Mellitus/metabolismo , Diabetes Mellitus/mortalidad , Humanos , Hipoglucemiantes/administración & dosificación , Inflamación/metabolismo , Inflamación/mortalidad , Fitoquímicos/aislamiento & purificación
9.
Curr Pharm Des ; 22(20): 2926-46, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26951101

RESUMEN

Globally, thrombosis-associated disorders are one of the main contributors to fatalities. Besides genetic influences, there are some acquired and environmental risk factors dominating thrombotic diseases. Although standard regimens have been used for a long time, many side effects still occur which can be life threatening. Therefore, natural products are good alternatives. Although the quest for antithrombotic natural products came to light only since the end of last century, in the last two decades, a considerable number of natural products showing antithrombotic activities (antiplatelet, anticoagulant and fibrinolytic) with no or minimal side effects have been reported. In this review, several natural products used as antithrombotic agents including medicinal plants, vegetables, fruits, spices and edible mushrooms which have been discovered in the last 15 years and their target sites (thrombogenic components, factors and thrombotic pathways) are described. In addition, the side effects, limitations and interactions of standard regimens with natural products are also discussed. The active compounds could serve as potential sources for future research on antithrombotic drug development. As a future direction, more advanced researches (in quest of the target cofactor or component involved in antithrombotic pathways) are warranted for the development of potential natural antithrombotic medications (alone or combined with standard regimens) to ensure maximum safety and efficacy.


Asunto(s)
Productos Biológicos/uso terapéutico , Descubrimiento de Drogas , Fibrinolíticos/uso terapéutico , Productos Biológicos/efectos adversos , Fibrinolíticos/efectos adversos , Humanos
10.
Curr Pharm Des ; 22(5): 549-65, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26601968

RESUMEN

Diabetes mellitus (DM) is one of the most common endocrine metabolic disorders. In addition to exercise and diet, oral anti-diabetic drugs have been used as a part of the management strategy worldwide. Unfortunately, none of the conventional anti-diabetic drugs are without side effects, and these drugs pose an economic burden. Therefore, the investigation of novel anti-diabetic regimens is a major challenge for researchers, in which nature has been the primary resource for the discovery of potential therapeutics. Many plants have been shown to act as anti-diabetic agents, in which the main active constituents are believed to be polyphenols. Natural products containing high polyphenol levels can control carbohydrate metabolism by various mechanisms, such as protecting and restoring beta-cell integrity, enhancing insulin releasing activity, and increasing cellular glucose uptake. Blackberries, red grapes, apricots, eggplant and popular drinks such as coffee, cocoa and green tea are all rich in polyphenols, which may dampen insulin resistance and be natural alternatives in the treatment of diabetes. Therefore, the aim of this review is to report on the available anti-diabetic polyphenols (medicinal plants, fruits and vegetables), their mechanisms in the various pathways of DM and their correlations with DM. Additionally, this review emphasizes the types of polyphenols that could be potential future resources in the treatment of DM via either novel regimens or as supplementary agents.


Asunto(s)
Diabetes Mellitus/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Polifenoles/uso terapéutico , Animales , Humanos
11.
Artículo en Inglés | MEDLINE | ID: mdl-25386217

RESUMEN

Diabetic wounds are unlike typical wounds in that they are slower to heal, making treatment with conventional topical medications an uphill process. Among several different alternative therapies, honey is an effective choice because it provides comparatively rapid wound healing. Although honey has been used as an alternative medicine for wound healing since ancient times, the application of honey to diabetic wounds has only recently been revived. Because honey has some unique natural features as a wound healer, it works even more effectively on diabetic wounds than on normal wounds. In addition, honey is known as an "all in one" remedy for diabetic wound healing because it can combat many microorganisms that are involved in the wound process and because it possesses antioxidant activity and controls inflammation. In this review, the potential role of honey's antibacterial activity on diabetic wound-related microorganisms and honey's clinical effectiveness in treating diabetic wounds based on the most recent studies is described. Additionally, ways in which honey can be used as a safer, faster, and effective healing agent for diabetic wounds in comparison with other synthetic medications in terms of microbial resistance and treatment costs are also described to support its traditional claims.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA